Zymeworks (ZYME) Gains from Investment Securities (2021 - 2026)
Zymeworks' (ZYME) quarterly Gains from Investment Securities came in at $245000.0 in Q1 2026, down 36.69% year-on-year from $387000.0 in Q1 2025, and up 119.71% quarter-over-quarter from -$1.2 million in Q4 2025.
Zymeworks (ZYME) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Gains from Investment Securities across 6 years of filings, most recently posting $245000.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $245000.0, down 36.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$998000.0 (down 145.86% YoY), and the FY2024 annual result was $3.2 million, up 404.6% from the prior year.
- Gains from Investment Securities came in at $245000.0 for Q1 2026 at Zymeworks, up from -$1.2 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $3.0 million in Q4 2024 to a low of -$1.2 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $11500.0 (2022), against an average of $129833.3.
- Peak annual rise in Gains from Investment Securities reached 381.66% in 2024, while the deepest fall reached 23460.0% in 2024.
- Zymeworks' Gains from Investment Securities stood at -$322000.0 in 2022, then jumped by 291.3% to $616000.0 in 2023, then surged by 381.66% to $3.0 million in 2024, then plunged by 141.89% to -$1.2 million in 2025, then soared by 119.71% to $245000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $245000.0 (Q1 2026), -$1.2 million (Q4 2025), and $387000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 245,000.00 |
| Mar 31, 2026 | 245,000.00 |
| Dec 31, 2025 | -1.24 Mn |
| Dec 31, 2025 | -1.24 Mn |
| Mar 31, 2025 | 387,000.00 |
| Mar 31, 2025 | 387,000.00 |
| Dec 31, 2024 | 2.97 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Dec 31, 2023 | 616,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |
| Dec 31, 2022 | -322,000.00 |
| Dec 31, 2022 | -322,000.00 |